The Swedish BioFINDER - Primary Care Study

RecruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Mild DementiaMild Cognitive ImpairmentSCDAlzheimer DiseaseLewy Body DiseaseFrontotemporal DegenerationVascular Dementia
Interventions
DIAGNOSTIC_TEST

Plasma APS 2 score

APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma p-tau217/np-tau217

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma p-tau217

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma neurofilament light (NfL)

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma Ab42/Ab40

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

MRI and CT of the brain

Structural brain imaging

DIAGNOSTIC_TEST

Different cognitive tests

Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.

Trial Locations (1)

Unknown

RECRUITING

Primary care centers in Region Skåne, Malmo

All Listed Sponsors
collaborator

Lund University

OTHER

lead

Skane University Hospital

OTHER